{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=22", "query": { "intervention": "Part 3", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 4019, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T13:20:45.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06533644", "title": "A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Partial Oncolysis", "type": "PROCEDURE" }, { "name": "SV-102", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Syncromune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 91, "start_date": "2025-05-29", "completion_date": "2028-04-14", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533644" }, { "nct_id": "NCT07645287", "title": "A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-3242 Tablet", "type": "DRUG" }, { "name": "GS-3242 Injection", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Lenacapavir Injection", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2026-06-15", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07645287" }, { "nct_id": "NCT01783704", "title": "Improving Community Ambulation After Hip Fracture", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hip Fracture" ], "interventions": [ { "name": "Nutrition", "type": "DIETARY_SUPPLEMENT" }, { "name": "PUSH", "type": "BEHAVIORAL" }, { "name": "PULSE", "type": "BEHAVIORAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "BEHAVIORAL" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 210, "start_date": "2013-06-10", "completion_date": "2017-10-17", "has_results": false, "last_update_posted_date": "2022-01-27", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 4, "location_summary": "Farmington, Connecticut • Baltimore, Maryland • Lebanon, New Hampshire + 1 more", "locations": [ { "city": "Farmington", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Glenside", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01783704" }, { "nct_id": "NCT01218204", "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidaemias", "Dyslipidemias" ], "interventions": [ { "name": "10mg atorvastatin", "type": "DRUG" }, { "name": "80mg atorvastatin", "type": "DRUG" }, { "name": "GSK1292263 Placebo", "type": "DRUG" }, { "name": "100mg GSK1292263", "type": "DRUG" }, { "name": "300mg GSK1292263", "type": "DRUG" }, { "name": "800mg GSK1292263", "type": "DRUG" }, { "name": "10mg ezetimibe", "type": "DRUG" }, { "name": "Washout", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 287, "start_date": "2010-09-14", "completion_date": "2011-06-29", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 21, "location_summary": "Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218204" }, { "nct_id": "NCT04903093", "title": "A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Abrocitinib tablet", "type": "DRUG" }, { "name": "Abrocitinib Suspension F1", "type": "DRUG" }, { "name": "Abrocitinib Suspension F2", "type": "DRUG" }, { "name": "Abrocitinib Suspension F3", "type": "DRUG" }, { "name": "Abrocitinib Suspension F4", "type": "DRUG" }, { "name": "Abrocitinib Suspension F5", "type": "DRUG" }, { "name": "Abrocitinib Suspension F6", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 19, "start_date": "2021-06-04", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903093" }, { "nct_id": "NCT02074293", "title": "ASIS for Botox in Cervical Dystonia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Dystonia Adults ,", "Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus." ], "interventions": [ { "name": "Gadolinium", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 6", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 12", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 18", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 24", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 30", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 6", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 18", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 24", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 30", "type": "DRUG" }, { "name": "Adverse Reactions of Botox intramuscularly", "type": "DRUG" }, { "name": "Adverse Reactions of Botox subdermally", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "li nguyen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074293" }, { "nct_id": "NCT04062214", "title": "Pragmatic RCT of SBIRT-PM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Substance Use Disorders", "Pain" ], "interventions": [ { "name": "SBIRT-PM", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1101, "start_date": "2019-10-23", "completion_date": "2024-04-11", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 9, "location_summary": "New Haven, Connecticut • West Haven, Connecticut • Augusta, Maine + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "Augusta", "state": "Maine" }, { "city": "Bedford", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04062214" }, { "nct_id": "NCT04526106", "title": "REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "FGFR2 Amplification", "FGFR2 Gene Mutation", "FGFR2 Gene Fusion/Rearrangement", "FGFR2 Gene Translocation", "FGFR2 Gene Activation", "Intrahepatic Cholangiocarcinoma", "Cholangiocarcinoma", "Other Solid Tumors, Adult" ], "interventions": [ { "name": "RLY-4008", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2020-09-02", "completion_date": "2025-09-05", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04526106" }, { "nct_id": "NCT02925884", "title": "Effects of Gunnar Computer Glasses on Viewing Comfort and Performance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dry Eye", "Eye Strain", "Visual Acuity", "Color Perception" ], "interventions": [ { "name": "Gunnar OTC Glasses", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Pacific University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "ALL", "summary": "18 Years to 42 Years" }, "enrollment_count": 35, "start_date": "2013-06", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 1, "location_summary": "Forest Grove, Oregon", "locations": [ { "city": "Forest Grove", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02925884" }, { "nct_id": "NCT05509439", "title": "Home Transfusion for HEME", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancy" ], "interventions": [ { "name": "Home Transfusion Program Components", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-10-18", "completion_date": "2025-05-21", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-11-11T13:20:45.460Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05509439" } ] }